A single dose of passive immunotherapy has extended benefits on synapses and neurites in an Alzheimer's disease mouse model
- PMID: 19465012
- PMCID: PMC2709805
- DOI: 10.1016/j.brainres.2009.05.045
A single dose of passive immunotherapy has extended benefits on synapses and neurites in an Alzheimer's disease mouse model
Abstract
Alzheimer's disease (AD) is a neurodegenerative disorder that impairs memory and cognition. One of the major neuropathological hallmarks is the accumulation of the extracellular senile plaques that are mainly composed of amyloid beta (Abeta) protein. Plaques are associated with synapse loss, dystrophic neurites and altered neurite trajectories. A reversal of such morphological changes has been observed days after single dose anti-Abeta immunotherapy. In this study we investigated the extended effects of a single dose of passive anti-Abeta immunotherapy on morphological changes associated with senile plaques. We found that although plaque burden was not reduced 30 days after immunotherapy, there were fewer dystrophic neurites around each plaque, a recovery of synapse density, and normalization of neurite curvature near plaques. Taken together these results suggest that a single dose of immunotherapy is sufficient to cause lasting benefits to the morphology of cortical neurons, implying substantial plasticity of neural circuits despite the continued presence of plaques.
Figures
![Fig 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2709805/bin/nihms119749f1.gif)
![Fig 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2709805/bin/nihms119749f2.gif)
![Fig 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2709805/bin/nihms119749f3.gif)
![Fig 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/2709805/bin/nihms119749f4.gif)
Similar articles
-
Human tau increases amyloid β plaque size but not amyloid β-mediated synapse loss in a novel mouse model of Alzheimer's disease.Eur J Neurosci. 2016 Dec;44(12):3056-3066. doi: 10.1111/ejn.13442. Epub 2016 Nov 12. Eur J Neurosci. 2016. PMID: 27748574 Free PMC article.
-
Amyloid-beta immunotherapy for Alzheimer's disease.CNS Neurol Disord Drug Targets. 2010 Apr;9(2):197-206. doi: 10.2174/187152710791012017. CNS Neurol Disord Drug Targets. 2010. PMID: 20205640 Free PMC article. Review.
-
Abeta immunotherapy protects morphology and survival of adult-born neurons in doubly transgenic APP/PS1 mice.J Neurosci. 2009 Nov 11;29(45):14108-19. doi: 10.1523/JNEUROSCI.2055-09.2009. J Neurosci. 2009. PMID: 19906959 Free PMC article.
-
Passive immunotherapy rapidly increases structural plasticity in a mouse model of Alzheimer disease.Neurobiol Dis. 2009 Feb;33(2):213-20. doi: 10.1016/j.nbd.2008.10.011. Epub 2008 Nov 6. Neurobiol Dis. 2009. PMID: 19028582 Free PMC article.
-
Neuronal structure is altered by amyloid plaques.Rev Neurosci. 2004;15(4):267-78. doi: 10.1515/revneuro.2004.15.4.267. Rev Neurosci. 2004. PMID: 15526551 Review.
Cited by
-
First-in-human, double-blind, placebo-controlled, single-dose escalation study of aducanumab (BIIB037) in mild-to-moderate Alzheimer's disease.Alzheimers Dement (N Y). 2016 Jun 20;2(3):169-176. doi: 10.1016/j.trci.2016.06.002. eCollection 2016 Sep. Alzheimers Dement (N Y). 2016. PMID: 29067304 Free PMC article.
-
Plaque-Associated Local Toxicity Increases over the Clinical Course of Alzheimer Disease.Am J Pathol. 2016 Feb;186(2):375-84. doi: 10.1016/j.ajpath.2015.10.010. Epub 2015 Dec 11. Am J Pathol. 2016. PMID: 26687817 Free PMC article.
-
Quaternary Structure Defines a Large Class of Amyloid-β Oligomers Neutralized by Sequestration.Cell Rep. 2015 Jun 23;11(11):1760-71. doi: 10.1016/j.celrep.2015.05.021. Epub 2015 Jun 4. Cell Rep. 2015. PMID: 26051935 Free PMC article.
-
Genetic modulation of soluble Aβ rescues cognitive and synaptic impairment in a mouse model of Alzheimer's disease.J Neurosci. 2014 Jun 4;34(23):7871-85. doi: 10.1523/JNEUROSCI.0572-14.2014. J Neurosci. 2014. PMID: 24899710 Free PMC article.
-
The intersection of amyloid beta and tau at synapses in Alzheimer's disease.Neuron. 2014 May 21;82(4):756-71. doi: 10.1016/j.neuron.2014.05.004. Neuron. 2014. PMID: 24853936 Free PMC article. Review.
References
-
- Arriagada P, Growdon J, Hedley-Whyte E, Hyman B. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer’s disease. Neurology. 1992;42:631–39. - PubMed
-
- Bacskai BJ, Kajdasz ST, Christie RH, Carter C, Games D, Seubert P, Schenk D, Hyman BT. Imaging of amyloid-beta deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy. Nat Med. 2001;7:369–72. - PubMed
-
- Bacskai BJ, Klunk WE, Mathis CA, Hyman BT. Imaging amyloid-beta deposits in vivo. J Cereb Blood Flow Metab. 2002;22:1035–41. - PubMed
-
- Bard F, Cannon C, Barbour R, Burke RL, Games D, Grajeda H, Guido T, Hu K, Huang J, Johnson-Wood K, Khan K, Kholodenko D, Lee M, Lieberburg I, Motter R, Nguyen M, Soriano F, Vasquez N, Weiss K, Welch B, Seubert P, Schenk D, Yednock T. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease. Nat Med. 2000;6:916–9. - PubMed